Offsetting Assets and Liabilities (Tables)

12 Months Ended

Dec. 31, 2019

Offsetting [Abstract]

Offsetting Assets

The composition of offsetting derivative instruments, financial assets, and financial liabilities was as follows.

	Gross amounts of recognized assets/liabilities		Gross amounts offset on the Consolidated Balance Sheet		Net amounts of assets/liabilities presented on the Consolidated Balance Sheet
							Gross amounts not offset on the Consolidated Balance Sheet
December 31, ($ in millions)							Financial instruments		Collateral (a) (b) (c)			Net amount
2019
Assets
Derivative assets in net asset positions (d)	$	62	$	—	$	62	$	—	$	(36	)	$	26
Derivative assets with no offsetting arrangements	2		—		2		—		—			2
Total assets	$	64	$	—	$	64	$	—	$	(36	)	$	28
Liabilities
Derivative liabilities in net liability positions (d)	$	5	$	—	$	5	$	—	$	(4	)	$	1
Total liabilities	$	5	$	—	$	5	$	—	$	(4	)	$	1
2018
Assets
Derivative assets in net asset positions	$	41	$	—	$	41	$	—	$	(4	)	$	37
Total assets (d)	$	41	$	—	$	41	$	—	$	(4	)	$	37
Liabilities
Derivative liabilities in net liability positions (d)	$	37	$	—	$	37	$	—	$	—		$	37
Securities sold under agreements to repurchase (e)	685		—		685		—		(685		)	—
Total liabilities	$	722	$	—	$	722	$	—	$	(685	)	$	37

(a) Financial collateral received/pledged shown as a balance based on the sum of all net asset and liability positions between Ally and each individual derivative counterparty.

(b) Amounts disclosed are limited to the financial asset or liability balance and, accordingly, exclude excess collateral received or pledged and noncash collateral received. There was $29 million and $3 million of noncash derivative collateral pledged to us that was excluded at December 31, 2019, and 2018, respectively, and $4 million of noncash collateral associated with our repurchase agreements pledged to us that was excluded at December 31, 2018. We do not record such collateral received on our Consolidated Balance Sheet unless certain conditions are met.

(c) Certain agreements grant us the right to sell or pledge the noncash assets we receive as collateral. Noncash collateral pledged to us where the agreement grants us the right to sell or pledge the underlying assets had a fair value of $29 million and $7 million at December 31, 2019, and 2018, respectively. We have not sold or pledged any of the noncash collateral received under these agreements as of both December 31, 2019, and December 31, 2018.

(d) For additional information on derivative instruments and hedging activities, refer to Note 21.

(e)

For additional information on securities sold under agreements to repurchase, refer to Note 15.

Offsetting Liabilities

The composition of offsetting derivative instruments, financial assets, and financial liabilities was as follows.

	Gross amounts of recognized assets/liabilities		Gross amounts offset on the Consolidated Balance Sheet		Net amounts of assets/liabilities presented on the Consolidated Balance Sheet
							Gross amounts not offset on the Consolidated Balance Sheet
December 31, ($ in millions)							Financial instruments		Collateral (a) (b) (c)			Net amount
2019
Assets
Derivative assets in net asset positions (d)	$	62	$	—	$	62	$	—	$	(36	)	$	26
Derivative assets with no offsetting arrangements	2		—		2		—		—			2
Total assets	$	64	$	—	$	64	$	—	$	(36	)	$	28
Liabilities
Derivative liabilities in net liability positions (d)	$	5	$	—	$	5	$	—	$	(4	)	$	1
Total liabilities	$	5	$	—	$	5	$	—	$	(4	)	$	1
2018
Assets
Derivative assets in net asset positions	$	41	$	—	$	41	$	—	$	(4	)	$	37
Total assets (d)	$	41	$	—	$	41	$	—	$	(4	)	$	37
Liabilities
Derivative liabilities in net liability positions (d)	$	37	$	—	$	37	$	—	$	—		$	37
Securities sold under agreements to repurchase (e)	685		—		685		—		(685		)	—
Total liabilities	$	722	$	—	$	722	$	—	$	(685	)	$	37

(a) Financial collateral received/pledged shown as a balance based on the sum of all net asset and liability positions between Ally and each individual derivative counterparty.

(b) Amounts disclosed are limited to the financial asset or liability balance and, accordingly, exclude excess collateral received or pledged and noncash collateral received. There was $29 million and $3 million of noncash derivative collateral pledged to us that was excluded at December 31, 2019, and 2018, respectively, and $4 million of noncash collateral associated with our repurchase agreements pledged to us that was excluded at December 31, 2018. We do not record such collateral received on our Consolidated Balance Sheet unless certain conditions are met.

(c) Certain agreements grant us the right to sell or pledge the noncash assets we receive as collateral. Noncash collateral pledged to us where the agreement grants us the right to sell or pledge the underlying assets had a fair value of $29 million and $7 million at December 31, 2019, and 2018, respectively. We have not sold or pledged any of the noncash collateral received under these agreements as of both December 31, 2019, and December 31, 2018.

(d) For additional information on derivative instruments and hedging activities, refer to Note 21.

(e)

For additional information on securities sold under agreements to repurchase, refer to Note 15.